China Regenerative Medicine International Limited (HKG:8158)
Hong Kong · Delayed Price · Currency is HKD 0.2320
+0.0120 (5.45%)
Aug 4, 2026, 11:43 AM HKT
HKG:8158 Balance Sheet
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.17 | 22.7 | 3.33 | 1.85 | 9.93 |
Cash & Short-Term Investments | 8.17 | 22.7 | 3.33 | 1.85 | 9.93 |
Cash Growth | -64.02% | 580.92% | 80.31% | -81.38% | 108.29% |
Accounts Receivable | 5.1 | 0.62 | 1.2 | 0.07 | 0.21 |
Other Receivables | 52.98 | 28.02 | 156.43 | 237.71 | 196.91 |
Receivables | 58.08 | 28.64 | 157.63 | 237.78 | 197.12 |
Inventory | 2.03 | 0.24 | 0.45 | 0.29 | 0.38 |
Prepaid Expenses | 0.26 | 0.16 | 0.19 | 2.56 | 41.36 |
Other Current Assets | 17.5 | 6.58 | 6.99 | 6.62 | 9.59 |
Total Current Assets | 86.04 | 58.31 | 168.58 | 249.09 | 258.39 |
Property, Plant & Equipment | 23.14 | 6.99 | 17.32 | 26.82 | 0.75 |
Other Long-Term Assets | 58.88 | 70.41 | - | - | - |
Total Assets | 168.06 | 135.71 | 185.9 | 275.91 | 259.14 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3 | 3.84 | 2.47 | 0.05 | 0.09 |
Accrued Expenses | 4.24 | 8.67 | 13.11 | 7.65 | 3.71 |
Current Portion of Long-Term Debt | 3.63 | 3.63 | 13.63 | 48.41 | 29.95 |
Current Portion of Leases | 8.46 | 4.59 | 10.4 | 9.92 | 5.87 |
Current Income Taxes Payable | 13.17 | 24.87 | 25.29 | 25.57 | 24.26 |
Current Unearned Revenue | 26.66 | 11.29 | 81.09 | 60.74 | 76.6 |
Other Current Liabilities | 16.06 | 1.98 | 1.81 | 5.82 | 6.83 |
Total Current Liabilities | 75.23 | 58.87 | 147.79 | 158.17 | 147.31 |
Long-Term Debt | 26.48 | 45.47 | 21.58 | - | - |
Long-Term Leases | 12.74 | - | 4.59 | 13.68 | - |
Long-Term Deferred Tax Liabilities | 0.15 | 0.15 | 0.15 | 0.15 | 0.1 |
Other Long-Term Liabilities | - | 6.02 | - | - | - |
Total Liabilities | 114.59 | 110.51 | 174.1 | 172 | 147.41 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 60.85 | 60.85 | 60.85 | 570.86 | 570.86 |
Additional Paid-In Capital | 3,216 | 3,216 | 3,216 | 3,204 | 3,204 |
Retained Earnings | -2,795 | -2,863 | -2,881 | -3,287 | -3,292 |
Comprehensive Income & Other | -428.09 | -388.23 | -383.88 | -383.46 | -371.09 |
Total Common Equity | 53.47 | 25.2 | 11.79 | 103.92 | 111.73 |
Shareholders' Equity | 53.47 | 25.2 | 11.79 | 103.92 | 111.73 |
Total Liabilities & Equity | 168.06 | 135.71 | 185.9 | 275.91 | 259.14 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 51.31 | 53.69 | 50.19 | 72.01 | 35.82 |
Net Cash (Debt) | -43.14 | -30.99 | -46.86 | -70.16 | -25.9 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.14 | -0.10 | -0.16 | -0.25 | -0.09 |
Filing Date Shares Outstanding | 304.25 | 304.25 | 304.25 | 285.43 | 285.43 |
Total Common Shares Outstanding | 304.25 | 304.25 | 304.25 | 285.43 | 285.43 |
Working Capital | 10.81 | -0.56 | 20.79 | 90.93 | 111.08 |
Book Value Per Share | 0.18 | 0.08 | 0.04 | 0.36 | 0.39 |
Tangible Book Value | 53.47 | 25.2 | 11.79 | 103.92 | 111.73 |
Tangible Book Value Per Share | 0.18 | 0.08 | 0.04 | 0.36 | 0.39 |
Machinery | 7.38 | 6.44 | 6.47 | 53.66 | 53.4 |
Leasehold Improvements | 22.19 | 22.19 | 21.74 | 104.15 | 101.82 |